Veterinary Medicines

Nobivac Ducat Lyophilisate and solvent for suspension for injection

Authorised
  • Feline rhinotracheitis virus, strain G2620A, Live
  • Feline calicivirus, strain F9, Live
Download as PDF

Product identification

Medicine name:
Nobivac Ducat Lyophilisate and solvent for suspension for injection
Nobivac Ducat
Active substance:
  • Feline rhinotracheitis virus, strain G2620A, Live
  • Feline calicivirus, strain F9, Live
Target species:
  • Cat
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Feline rhinotracheitis virus, strain G2620A, Live
    4.80
    log10 tissue culture infective dose 50
    /
    1.00
    Dose
  • Feline calicivirus, strain F9, Live
    4.60
    log10 plaque forming unit(s)
    /
    1.00
    Dose
Pharmaceutical form:
  • Lyophilisate and solvent for suspension for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Cat
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI06AD03
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Norway
Package description:
  • (ID44): 1 Box with 50 Box with (1 Bottle (Glass) with 1 Dose and 1 Bottle (Glass) with 1 millilitre(s)) (50 Dose, 50 millilitre(s))
  • (ID34): 1 Box with 25 Box with (1 Bottle (Glass) with 1 Dose and 1 Bottle (Glass) with 1 millilitre(s)) (25 Dose, 25 millilitre(s))
  • (ID24): 1 Box with 10 Box with (1 Bottle (Glass) with 1 Dose and 1 Bottle (Glass) with 1 millilitre(s)) (10 Dose, 10 millilitre(s))
  • (ID14): 1 Box with 5 Box with (1 Bottle (Glass) with 1 Dose and 1 Bottle (Glass) with 1 millilitre(s)) (5 Dose, 5 millilitre(s))

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Immunological veterinary medicinal product application (Article 13d of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Intervet International B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
  • INTERVET INTERNATIONAL B.V.
Responsible authority:
  • Norwegian Medical Products Agency
Authorisation number:
  • 04-2651
Date of authorisation status change:
Reference member state:
  • Germany
Procedure number:
  • DE/V/0207/001
Concerned member states:
  • Austria
  • Belgium
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Greece
  • Ireland
  • Latvia
  • Lithuania
  • Luxembourg
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Sweden
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

English (PDF)
Published on: 13/03/2023
Download
Norwegian (PDF)
Published on: 11/05/2023
Download

Package Leaflet

English (PDF)
Published on: 16/03/2023
Download
Norwegian (PDF)
Published on: 11/05/2023
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."